SCHEMBL30855296

SCHEMBL30855296

COc1ccccc1N1CCN(CC[C@H]2CC[C@H](N)CC2)CC1

nearest known ligand 0.66

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.66
DRD3 P35462 4/20 0.66
SLC6A2 P23975 1/20 0.58
SLC6A4 P31645 1/20 0.58
ADRA1D P25100 1/20 0.57
ADRA1A P35348 1/20 0.57
ADRA1B P35368 1/20 0.57
HTR1A P08908 1/20 0.57
HTR2C P28335 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3848845 1.00 DRD2 (0.66) DRD2DRD3SLC6A2SLC6A4ADRA1D
SCHEMBL30855329 0.88 DRD2 (0.66) DRD2DRD3SLC6A2SLC6A4ADRA1D
SCHEMBL3848840 0.85 DRD2 (0.61) DRD2DRD3HTR1AHTR2C
Hydrochloric Acid SCHEMBL4076895 0.84 DRD2 (0.53) DRD2DRD3SLC6A2SLC6A4ADRA1D
Hydrochloric Acid SCHEMBL4076893 0.84 DRD2 (0.53) DRD2DRD3SLC6A2SLC6A4ADRA1D
SCHEMBL4082053 0.83 DRD2 (0.57) DRD2DRD3ADRA1DADRA1AADRA1B
SCHEMBL4502971 0.83 DRD2 (0.65) DRD2DRD3ADRA1DADRA1AADRA1B
Hydrochloric Acid SCHEMBL3329691 0.81 DRD2 (0.63) DRD2DRD3SLC6A4ADRA1DADRA1A
Hydrochloric Acid SCHEMBL3329696 0.81 DRD2 (0.63) DRD2DRD3SLC6A4ADRA1DADRA1A
SCHEMBL3847619 0.81 DRD2 (0.65) DRD2DRD3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594294-A1 DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2025-08-06 EP disclosed
WO-2024072930-A1 DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-04-04 WO disclosed